The test identifies carriers of a genetic variant found in up to 60% of Alzheimer's patients, helping clinicians triage patients and guide treatment decisions.
20/20 BioLabs argues a tiered screening approach—starting with protein-based tests before moving to circulating tumor DNA testing or imaging—could improve early-stage detection and lower costs.
The Galleri blood test demonstrated a four-fold increase in cancer detection rates and substantial reduction in stage IV cancer diagnoses in 142,000 participants.
The FDA has granted Breakthrough Device Designation to Breath Diagnostics Inc.'s OneBreath, a breath-based test that assesses postoperative pneumonia risk in cardiac surgery patients using a single preoperative sample.
Utah State researchers have identified new CRISPR-Cas12a3 functions that selectively target pathogen RNA without harming host DNA, potentially enabling a single diagnostic test for COVID-19, flu, and RSVV..
HerAnova Lifesciences has launched HerResolve, the first blood-based test for endometriosis detection, at IVF centers nationwide. Validation studies show diagnostic accuracy comparable to surgical standards, according to the company.
Researchers at JAX and MIT have developed a microneedle patch that samples immune cells from skin within hours, providing a noninvasive alternative to blood draws and biopsies.
The test measures two sugar alcohols to detect SORD-related neuropathy, which standard genetic tests sometimes miss.
The collaboration will expand access to Alzheimer's biomarker testing through mobile delivery to community centers, churches, and senior centers nationwide.
Researchers at UC San Diego have developed the MAPI score, a blood test using five standard lab values to distinguish alcohol-related liver injury from metabolic causes, according to a study in Gastroenterology.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
Research in bone marrow transplant patients with blood cancers and febrile neutropenia suggests the host-response test may help identify infection in high-risk populations.